



OMKAR
Always the leaders

OMKAR SPECIALITY CHEMICALS LIMITED

Regd. & Corporate Office : Unit - III, B-34, M.I.D.C., Badlapur (East), Thane - 421 503, Maharashtra, India
Tel. : +91 (0251) 2697340, 2690651, Fax : +91 (0251) 2697347, 2691572
Email : info@omkarchemicals.com Web. : www.omkarchemicals.com

CIN : L24110MH2005PLC151589

Ref. No.: OSCL/SE/2016-17/20

Date: May 24, 2016

To,

Corporate Services Department BSE LIMITED P.J. Towers, 1 st Floor, Dalal Street, Mumbai – 400001. BSE Code: 533317	Corporate Services Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400051. NSE Symbol: OMKARCHEM
--	--

Ref.: Intimation of Conference Call – Reg. 30

Dear Sir / Madam,

In furtherance of our letter dated May 23, 2016, Ref.: No.: OSCL/SE/2016-17/18, we are enclosing Presentation and Media Release for Concall scheduled to be held on May 25, 2016 for Audited Financial Results of the Company for the quarter and year ended March 31, 2016.

Kindly take the same on record and acknowledge receipt.

Thanking You,

Yours truly,
For **OMKAR SPECIALITY CHEMICALS LIMITED**


SUNNY PAGARE
COMPANY SECRETARY & COMPLIANCE OFFICER
M. NO.: A27431





Omkar Speciality Chemicals Limited

Q4 FY16 Earnings Presentation

May 25, 2016

Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Omkar Speciality Chemicals Limited (the “Company”) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

Table of Contents

01

Director's Message

02

Financial Highlights

03

Segment-wise / Geographical Break up of Revenues

04

Business Overview

Director's Message



Mr. Omkar Herlerkar,
Wholetime Director,


“We have demonstrated strong growth across all our different business segments driven by increased demand for specialty chemicals from India. Our focus on higher operating efficiencies, productivity, innovation and process excellence has started to yield results as you can see in our fourth quarter numbers.

Going forward, we plan to bring business growth through a leased model of contract manufacturing in our specialty chemicals business. This will not only take care of higher capacity requirement but also make us more efficient.


With new capacity in place in the Vet API business combined with plans to add new products this year and enter new markets, we are confident that this business will demonstrate a higher double digit growth over the next 2-3 years.”

Financial Highlights (Q4 FY16 v/s Q4 FY15)


Total Income (Rs. Cr.)




EBITDA (Rs. Cr.)



EBIT (Rs. Cr.)




PAT (Rs. Cr.)




- Change in **Product Mix and higher capacity utilisation** led to 550 bps YoY increase in EBITDA margin at 24.60 %
- **Tax** - Paid Rs. 12cr Tax in Q4FY16 as against Tax Write back of Rs. 2 cr in Q4FY15

Financial Highlights (FY2016 v/s FY2015)


Total Income (Rs. Cr.)




EBITDA (Rs. Cr.)



EBIT (Rs. Cr.)



PAT (Rs. Cr.)





- EBITDA Margin stood flat at 19.6% while **EBIT Margin improved by over 150 basis points at 17.7%**
- Higher tax rate on account of higher Deferred Tax Liability (Rs. 11 Cr in FY16 vs Rs. 1 Cr in FY15)

Segment & Geographical Revenue Split



Q4 FY16

Segment break-up

FY16




Geographical break-up




Key Performance Indicators

Return on Equity*



Return on Capital Employed*




- Return Ratios improving steadily on account of change in product mix
- Company's endeavour is to focus on higher margin products


* ROE = PAT / Networth; ROCE = EBIT/ Capital Employed

Key Performance Indicators


Networth (Rs Cr.)



Net Debt/Equity



Net Working Capital (Days)



Quarterly Performance - P&L Statement

Particulars (Rs. Cr.)	Q4FY16	Q4FY15	Y-o-Y % Chg	Q3FY16	Q-o-Q % Chg
Revenue from Operations	113.3	73.9	53.4	108.3	4.6
Raw Material & Fuel costs	75.2	45.0	67.3	80.1	-6.1
Employee Cost	5.4	3.8	40.4	4.4	22.4
Other costs	4.9	11.1	-55.3	6.4	-22.3
Total Expenditure	85.5	59.8	42.9	90.8	-5.9
EBITDA	27.8	14.0	98.1	17.5	59.0
EBITDA Margin (%)	24.6	19.0		16.2%	
Depreciation	3.2	6.8	-53.0	2.0	58.1
Other Income	0.5	0.0	11.6	0.3	-83.8
Interest	8.2	4.0	107.4	4.0	104.3
Excep. Item	0.5	-	-	-	-
Profit Before Tax	16.5	3.4	389.1	11.8	39.8
Tax	12.4	-2.1	-703.8	2.4	422.6
Profit After Tax	4.0	5.4	-25.6	9.4	-57.1
PAT Margin (%)	3.6	7.3		8.7%	

Annual Consolidated P&L Statement

Particulars (Rs. Cr.)	FY16	FY15	% Chg
Revenue from Operations	413.4	265.1	55.9
Raw Material & Fuel costs	290.0	167.7	72.9
Employee Cost	18.0	14.4	24.7
Other costs	24.6	30.9	-20.4
Total Expenditure	332.6	213.0	56.1
EBIDTA	80.8	52.1	55.1
EBITDA Margin (%)	19.6%	19.7%	
Depreciation	9.0	10.3	-12.6
Other Income	1.4	0.9	
Interest	20.4	14.5	40.7
Excep. Item	0.5	-	
Profit Before Tax	52.4	28.2	85.8
Tax	21.8	4.0	443.8
Profit After Tax	30.6	24.2	26.5
PAT Margin (%)	7.4%	9.1%	

Annual Consolidated Balance Sheet Highlights

Rs crore	Mar-16	Mar-15
Shareholder's Funds	195.5	169.0
Share capital	20.6	21.0
Reserves & Surplus	174.9	148.0
Non-current liabilities	108.5	63.0
Long term borrowings	94.5	61.0
Defer Tax liabilities	11.3	1.0
Other Long-Term liabilities	-	-
Long-Term Provisions	2.8	2.0
Current liabilities	278.9	248.0
Short Term Borrowings	113.1	141.0
Trade Payables	98.2	61.0
Other Current liabilities	46.9	33.0
Short-term provisions	20.7	13.0
Total Equities & Liabilities	582.9	479.0

Rs crore	Mar-16	Mar-15
Non-current assets	310.9	272.0
Fixed assets	309.6	271.0
Non-current Investments	0.1	0.0
Long-term loans & advances	0.9	1.0
Other non-current assets	0.4	0.0
Current assets	272.0	207.0
Current investments	0.0	0.0
Inventories	99.9	89.0
Trade receivables	130.4	77.0
Cash & Cash equivalents	10.3	16.0
Short-term loans & Advances	30.5	3.0
Other Current Assets	1.0	24.0
Total Assets	582.9	479.0

Developments during the Year

- **Received Environment Clearance for Chiplun facility**
 - ✓ Manufacturing of Vet API
 - ✓ Additional infrastructure being put in place to start operations
- **Board of Directors approved Merger-Demerger scheme of Company**
 - ✓ Merging four subsidiaries into one and demerging Vet API business into separate entity called Lasa Supergenerics Ltd. – to be listed on both exchanges
 - ✓ For every one share of Omkar Speciality held, the shareholders to get one share of Lasa Supergenerics.
 - ✓ New entity to be renamed as Lasa Laboratories Ltd.
 - ✓ Scheme given for SEBI approval and entire process likely to be completed by end of this calendar year



Performance Highlights

For the quarter ended March 31, 2016:

- Revenue from operations stands at **Rs. 113 crore** in **Q4FY16**, as against Rs. 74 crore in the corresponding previous period, a **YoY growth of 53%**
- Breakup of revenue as per business segments:
 - **API segment** – 29% of total revenue
 - **Intermediates segment** – 32% of total revenue
 - **Iodine Derivatives segment** – 25% of total revenue
 - **Resolving Agents segment** – 2% of total revenue
 - **Selenium Derivatives segment** – 12% of total revenue
- **EBITDA stood at Rs. 28 crore** in Q4FY16 as against Rs. 14 crore in the corresponding previous period and **grew by 99% YoY**, mainly on account of **better product mix and reduction in Other Expenses**.
- **EBITDA margin at 24.6%**, an improvement of **over 500 basis points YoY** mainly by increasing the production at our facilities and reducing the processing at outside units and freight management.
- **Profit After Tax stands at Rs. 4 crore** in Q4FY16 as against Rs. 5.4 crore in Q4FY15, **YoY decline of 25.9%** due to provisioning of **Rs. 698.33 lakhs** towards **Deferred Tax** for earlier years.

For the year ended March 31, 2016:

- Revenue from operations is **Rs. 413 crore** in **FY16**, as against Rs. 265 crore in FY15 period, a **growth of 56% over FY15**
- **Exports** contributed to **14% of revenues**
- Breakup of revenue as per business segments:
 - **API segment** – 31% of total revenue
 - **Intermediates segment** – 38 of total revenue
 - **Iodine Derivatives segment** – 23% of total revenue
 - **Resolving Agents segment** – 2% of total revenue
 - **Selenium Derivatives segment** – 6% of total revenue
- **EBITDA at Rs. 81 crore** in FY16 as against Rs. 52 crore last year, **grew by 55%**
- **EBITDA margin at 19.6%** remained flat on account of higher raw material costs, but managed to control other expenses to compensate the gap of higher cost
- **Profit After Tax stands at Rs. 31 crore** in FY16 as against Rs. 24 crore last year, **grew by 26%**

For further information, please contact:

Company :

Omkar Speciality Chemicals Ltd
CIN: L24110MH2005PLC151589

Mr. Omkar Herlekar
omkar@omkarchemicals.com

www.omkarchemicals.com

Investor Relations Advisors :

Bridge Investor Relations Pvt Ltd
CIN: U74900MH2016PTC273679

Ms. Savli Mangle
savli@bridge-ir.com

Mr. Amit Sharma
amit@bridge-ir.com

www.bridge-ir.com





Media Release

Strong Growth across all business segments

Revenues from operations at Rs.413 crore, YoY growth of 56%

EBITDA at Rs. 81 crore, YoY growth of 55%

EBIDTA margins at 19.6%

PAT at Rs. 30.6 crore, YoY growth of 26.6%

Mumbai, May 25, 2016: Omkar Speciality Chemicals Limited (BSE: 533317, NSE: OMKARCHEM), a leading player involved in the manufacturing of Speciality Chemicals and Veterinary APIs, announced its results for the quarter and full year ended 31st March 2016.

Key Financials (Rs. In Crore) :

Particulars	Q4FY16	Q4FY15	YoY%	FY16	FY15	YoY%
Net Sales	113.3	73.9	53.4	413.4	265.1	55.9
EBITDA	27.8	14.0	98.1	80.8	52.1	55.1
PAT	4.0	5.4	(25.7)	30.6	24.2	26.55

Management Comments:

Commenting on the results, Mr. Omkar Herlekar, Wholetime Director, Omkar Speciality Chemicals Ltd said: *"We have demonstrated strong growth across all our different business segments driven by increased demand for specialty chemicals from India. Our focus on higher operating efficiencies, productivity, innovation and process excellence has started to yield results as you can see in our fourth quarter numbers.*

Going forward, we plan to bring business growth through a leased model of contract manufacturing in our specialty chemicals business. This will not only take care of higher capacity requirement but also make us more efficient.

With new capacity in place in the Vet API business combined with plans to add new products this year and enter new markets, we are confident that this business will demonstrate a higher double digit growth over the next 2-3 years."



Balance Sheet as on March 31, 2016:

- The **Networth** stood at **Rs. 195 crore** as against Rs. 169crore as on March 31, 2015, **an increase of 16%**
- **Long Term Debts** are at **Rs. 90 crore** as against Rs. 60 crore as on March 31, 2015, on account a new corporate loan sanctioned by BOB to reduce the pressure on short term borrowings.
- **The Total debt** at **Rs. 206 crore** as against Rs. 202 crore as on March 31, 2015.
- Working Capital days have been brought down from 145 days in FY15 to 116 days in FY16 due to Company's efforts to reduce the inventory level and reduction in outstanding with Debtors.

Developments during FY16

- **Received Environment Clearance for it new facility at Chiplun.**
 - This facility is into manufacturing of Veterinary API
 - The Company has worked towards putting in place the additional infrastructure required to start operations
 - The operation is likely to commence in quarter three.
- **The Board of Directors approved the Merger-Demerger scheme**
 - The Company is merging its four subsidiaries into one and simultaneously demerging the Vet API business into a separate entity called Lasa Supergenerics Ltd. which will be listed on the exchanges
 - For every share of Omkar Speciality held, the shareholders will get one share of Lasa Supergenerics
 - The new entity will be renamed as Lasa Laboratories Ltd.
 - The Scheme has been filed with for SEBI approval and entire process likely to be completed by end of this calendar year



Earnings Conference Call – Q4 FY16

The conference call details are as under:

Date: 25th May 2016

Time: 16:00 hours

Dial-in Numbers: +91 22 6746 5969 / +91 22 3960 0860

About Omkar Speciality Chemicals Limited:

Omkar Speciality Chemicals Limited is amongst the leading manufacturers of Specialty Chemicals and Intermediates for Chemical and Allied Industries. The Company has total 8 Units, of which 4 Units are located in Badlapur, and the other 3 units are located in Chiplun, Ratnagiri and in Mahad.

Omkar Speciality Chemicals Limited exports to over 38 countries across Europe, Canada, Asia, South America & Australia. The Company's association with leading organizations in India and abroad has expanded their business, across different product lines and develop new molecules as per the specific requirements of their valued customers.

For more details please visit: www.omkarchemicals.com

For any Investor Relations query, please contact:

Omkar Herlekar	Savli Mangle / Amit Sharma
Whole Time Director	Bridge Investor Relations Pvt Ltd
Omkar Speciality Chemicals Limited	Phone: +91-22-26873003
Email: omkar@omkarchemicals.com	Email: savli@bridge-ir.com / amit@bridge-ir.com

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward looking statements. Omkar Speciality Chemicals Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*